Result:Weak· Market: Flat#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 6.08 | 207.6% | 4.8% |
| Total Income | 6.22 | 188.2% | 5.6% |
| Expenditure | 6.06 | 141.2% | 7.3% |
| PBT | 0.15 | 143.3% | 34.6% |
| Net Profit | 0.15 | 73.5% | 34.6% |
| OPM | 0.76% | 26.30pp | 2.28pp |
| NPM | 2.48% | 24.56pp | 1.53pp |
| EPS | 0.52 | 73.3% | 41.6% |
Adjusted net profit fell 34.6% YoY with margin compression (OPM 3.04%→0.76%, NPM 4.01%→2.48%) despite modest revenue growth, indicating below-par core profitability for a small pharma name.
Informational and educational content only. Not investment advice.